创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels: Introduction of iHuPDX model features

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-11 15:46
  • Views:

(Summary description)With the rapid development of biotechnology, people's understanding of diseases and means of treatment are also deepening. Against this background, the iHuPDX model introduced by InnoModels has opened up a new path for biomedical research with its unique features

InnoModels: Introduction of iHuPDX model features

(Summary description)With the rapid development of biotechnology, people's understanding of diseases and means of treatment are also deepening. Against this background, the iHuPDX model introduced by InnoModels has opened up a new path for biomedical research with its unique features

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-11 15:46
  • Views:
Information

With the rapid development of biotechnology, people's understanding of diseases and means of treatment are also deepening. Against this background, the iHuPDX model introduced by InnoModels has opened up a new path for biomedical research with its unique features.
I. Homogenized modeling of the same batch of samples
InnoModels Bio's iHuPDX model ensures homogenization of samples between batches by modeling cell suspensions. This means that there is a high degree of consistency in the growth rate and biological characteristics of individual samples within the same batch. This homogenization modeling method not only lays a solid foundation for the stability of the model, but also provides a strong guarantee for the reliability and reproducibility of the experimental results.

 


Stability and Consistency of Same-Generation Transmission
The homogenization of the same batch of samples ensures the stability of the same generation and after the transmission. In the long-term research process, the iHuPDX model can maintain consistent growth and efficacy characteristics, which makes the experimental results more reliable. This stability and consistency of sibling transmission makes the model have a wide range of application prospects in the fields of drug development and disease treatment.
Early and uniform growth, optimal efficacy experimental window
The iHuPDX model of InnoModels Biotechnology provides an optimal experimental window for efficacy experiments by realizing uniform growth at an early stage. Conducting efficacy experiments in the P2-P5 generation can more accurately reflect the therapeutic effect of the drug on the disease, providing strong support for drug development. At the same time, the early uniform growth characteristics also make the model more advantageous in disease simulation and treatment strategy research.
In conclusion, the iHuPDX model of InnoModels provides a new perspective and tool for biomedical research with its unique features of homogenization modeling of samples from the same batch, stability and consistency of sibling transmission, and early uniform growth. The application of this model is expected to promote the development of personalized medicine and make greater contributions to human health.

Keyword:

In the field of life sciences, every leap in technology leads to deeper research and medical advances. InnoModels Biotechnology (Beijing) Co., Ltd, with its innovative 3D organoid platform, is providing scientists with an unprecedented research tool, which greatly promotes drug research and development and the exploration of disease mechanisms
In the vast starry sky of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. is like a bright star, illuminating the journey of oncology and tumor immunology drug development with its unique PDX in vivo efficacy model. Today, let's go into InnoModels Biotechnology to learn more about its industry-leading PDX in vivo efficacy model and explore its unlimited potential in drug discovery and development.
In the vast field of cancer research and drug development, InnoModels Biotechnology (Beijing) Co., Ltd. provides powerful support to scientists and doctors with its leading CDX (Cell line-derived xenograft tumor) model platform. The platform not only has diverse tumor cell lines, but also is equipped with a team of experienced experts and advanced experimental technologies, which are dedicated to promoting innovation in biomedical research and clinical treatment.
In the field of life sciences, in vitro killing experimental platform is gradually becoming an important tool for drug development and cell research. Among them, the in vitro killing experimental platform of InnoModels Biotechnology has attracted the attention of many researchers with its unique technical advantages and wide application prospects. In this paper, we will introduce in detail the features and advantages of InnoModels' in vitro killing platform and its applications in scientific research.
In the vast starry sky of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. is leading the forefront of tumor and tumor immunotherapy research with its unique in vivo tumor experimental platform, which is like a bright star. The platform not only integrates the most advanced technologies and experimental methods, but also devotes itself to providing a new generation of experimental animal models close to the clinic
In the vast field of life science and drug discovery, in vitro experimental platforms play a crucial role. As a leader in this field, InnoModels Biotechnology (Beijing) Co., Ltd. provides scientists with a highly controlled and precise experimental environment with its in vitro killing platform, which greatly facilitates the screening of new drugs, the study of drug mechanisms, and the development of immunotherapies.
Previous page
1
2
42

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司